PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.
Maria Vidal
No relevant relationships to disclose
Lorena De La Pena
No relevant relationships to disclose
Mafalda Oliveira
No relevant relationships to disclose
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Antonio Llombart
Consultant or Advisory Role - GlaxoSmithKline; Roche
Honoraria - Roche; Teva
Aleix Prat
No relevant relationships to disclose